Ultime notizie per Repligen (NASDAQ:RGEN) Azioni

Repligen

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen Corp

Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $188.33, a high estimate of $205.00, and a low estimate of $170.00. This current average represents a 1.91% decrease from the previous average price target of $192.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1727362824_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Repligen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Repligen. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Repligen compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Repligen's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Repligen's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RGEN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Repligen analyst ratings.</a>
<h2>All You Need to Know About Repligen</h2>
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
<h3>Repligen: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Repligen's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -3.2%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Repligen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Repligen's ROE stands out, surpassing industry averages. With an impressive ROE of 0.17%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Repligen's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.12% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Repligen's debt-to-equity ratio is below the industry average at 0.37, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

RGEN

Evaluating Repligen: Insights From 6 Financial Analysts

RBC Capital analyst Conor McNamara reiterates Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Outperform and maintains $205 price target.

News

Price Target

Reiteration

RBC Capital Reiterates Outperform on Repligen, Maintains $205 Price Target

Repligen To Restate Financial Statements For 2023 And Early 2024, No Impact On Business Operations Or Strategic Outlook; Reaffirms 2024 Revenue Guidance, Adjusting FY Range To $627M-$642M After $6.6M Understatement

Wells Fargo analyst Brandon Couillard initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Overweight rating and announces Price Target of $180.

Initiation

Wells Fargo Initiates Coverage On Repligen with Overweight Rating, Announces Price Target of $180

General

Repligen shares are trading lower following a report suggesting the company has approached Maravai LifeSciences with a takeover offer.

Wall Street edged slightly higher on Friday, with major equity indices showing modest gains <a href="https://www.benzinga.com/markets">at midday in New York.</a>
Both the S&amp;P 500 and Nasdaq 100 are on track to record their best week since October 2023, driven by stronger-than-expected economic data that eased earlier concerns of a recession. If they close in the green, they will secure the seventh straight positive session. 
On Friday, the University of Michigan&#8217;s Consumer Sentiment Index for August exceeded expectations, adding to a series of positive data, including lower-than-anticipated jobless claims and strong retail sales growth reported the day before.
Gold was the standout performer, climbing 1.5% to reach a record high of $2,500 per ounce, as traders positioned themselves in anticipation of imminent Federal Reserve rate cuts.
This surge in gold prices boosted gold mining stocks, with the VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>) advancing over 2%.
Oil prices, however, dipped 1.6% amid reduced geopolitical tensions as Gaza ceasefire negotiations resumed in Doha, Qatar. In a joint statement, the United States, Qatar, and Egypt announced that Washington had presented a new proposal that has the potential to rapidly close gaps and lead to a swift agreement.
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.6%, reaching $58,368.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,142.44</td>
<td>0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,552.80</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,619.51</td>
<td>0.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,507.26</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent081624&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;was 0.1% higher to $553.81.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;also rose 0.1% to $406.32.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.2% up to $475.31.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) ticked 0.2% higher to $212.42.</li>
<li>The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>), The Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>), and The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up by 0.5%. The Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) lagged, down by 0.5%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul>
<li>H&amp;R Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) rallied 15% following stronger-than-expected results last quarter.</li>
<li>Other stocks moving on earnings were Amcor plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>), down 5%, Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), down 1.5%, Coherent Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>), up 8%, Flower Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>), down 0.3%, and Globant S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>), up 4.9%. </li>
<li>Repligen Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) dropped 13% after making an acquisition offer to Maravai LifeSciences Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>), a company specializing in vaccine capping reagents with a market value of $2.2 billion. Following the offer, Maravai&#8217;s shares surged by 23%.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40420968/walmart-stock-one-of-the-most-compelling-retail-investments-7-analysts-highlight-ma">Walmart Stock &#8216;One Of The Most Compelling&#8217; Retail Investments: 7 Analysts Highlight Market Share Gains</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Tech

ETFs

$BTC

AMAT

AMCR

COHR

SPDR Dow Jones Industrial Average ETF Trust

Market Vectors ETF Trust Market Vectors Gold Miners

GLOB

MRVI

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Gains Ground As Consumer Sentiment Improves; Gold Hits Record Highs, Boosting Mining Stocks: What's Driving Markets Friday?

Trading Ideas

Repligen Corp Has Approached Maravai LifeSciences Holdings Inc With An Acquisition Offer; Maravai LifeSciences  Shares Halted To The Upside; Stock Up 11.17%

Benchmark analyst Robert Wasserman reiterates Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Hold.

Benchmark Reiterates Hold on Repligen

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares jumped 65.95%. The company reached a supply agreement with Corning for next-generation fiber-optic cables to <a href="https://www.benzinga.com//node/40104952" target="_blank" rel="noreferrer noopener">support AI demands in data centers</a>.</li>
<li>Shake Shack, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) shares escalated 19.52% after the company reported <a href="https://www.benzinga.com//node/40104675" target="_blank" rel="noreferrer noopener">better-than-expected Q2 sales results</a>. Several analysts increased <a href="https://www.benzinga.com//node/40131307" target="_blank" rel="noreferrer noopener">their forecasts for the company</a>.</li>
<li>Parsons Corp NYSE: PSN) stock gained 15.42% after it reported better-than-expected Q2 results and raised its FY24 revenue outlook.</li>
<li>Clearwater Analytics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) stock increased 15.23% after the company reported better-than-expected Q2 sales results and issued Q3 and FY24 <a href="https://www.benzinga.com//node/40081350" target="_blank" rel="noreferrer noopener">revenue guidance above estimates</a>.</li>
<li>Repligen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) stock upped 15.14%. The company reported <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40044492/repligen-lowers-guidance-on-china-weakness-analyst-expects" target="_blank" rel="noreferrer noopener">Q2 earnings</a>, after which several analysts revised their price forecasts.</li>
<li>Frontdoor Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) stock gained 15.09% following better-than-expected Q2 earnings.</li>
<li>NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) stock upped 14.47% after the company reported better-than-expected Q2 financial results and <a href="https://www.benzinga.com//node/40021917" target="_blank" rel="noreferrer noopener">raised its FY24 revenue guidance</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40150484/microstrategy-intel-and-moderna-are-among-top-12-large-cap-losers-last-week-july-28-august-3-are-the" target="_blank" rel="noreferrer noopener">MicroStrategy, Intel And Moderna Are Among Top 12 Large Cap Losers Last Week (July 28-August 3): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/24/08/40150236/doordash-and-exact-sciences-are-among-top-10-large-cap-gainers-last-week-july-28-aug-3-are-the-other" target="_blank" rel="noreferrer noopener">DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?</a></li>
</ul>
Photo by YAO23 via Shutterstock

Movers

ACHC

CVLT

CWAN

DRVN

FTDR

HWKN

IDCC

LUMN

SHAK

ZETA

Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?

Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) reported in-line earnings for its <a href="https://www.benzinga.com/quote/RGEN/earnings">second quarter on Tuesday</a>.
The company posted second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million. The company reported an adjusted EPS of 33 cents, which is in line with the consensus but below $0.53 reported a year ago.
Tony J. Hunt, CEO of Repligen, said, "We delivered solid second-quarter revenue of $154 million and first-half revenue of $305 million, achieving our year-to-date sales target. We are very encouraged by orders in the quarter, with continued strength in Pharma demand and a pickup in CDMO activity. New modalities continued to show strong year-over-year momentum in both revenue and orders."
Repligen expects 2024 revenues of $620 million—$635 million, compared to prior guidance of $620 million—$650 million and the consensus of $636.6 million.
Repligen shares gained 5.3% to trade at $169.16 on Wednesday.
These analysts made changes to their price targets on Repligen following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/62dfc8fc8032230001a272b4/rachel-vatnsdal">JP Morgan analyst Rachel Vatnsdal</a> maintained Repligen with an Overweight and raised the price target from $190 to $200.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/62d7f4a480322300019cafd5/elizabeth-garcia">UBS analyst Elizabeth Garcia</a> maintained Repligen with a Buy rating, while cutting the price target from $205 to $185.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would">Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: &#8216;I Would Pick Some Up Tomorrow&#8217;</a></li>
</ul>

Earnings

Markets

These Analysts Revise Their Forecasts On Repligen Following Q2 Results

JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Overweight and raises the price target from $190 to $200.

JP Morgan Maintains Overweight on Repligen, Raises Price Target to $200

UBS analyst Elizabeth Garcia maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Buy and lowers the price target from $205 to $185.

UBS Maintains Buy on Repligen, Lowers Price Target to $185

RBC Capital analyst Conor McNamara reiterates Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Outperform and maintains $190 price target.

RBC Capital Reiterates Outperform on Repligen, Maintains $190 Price Target

Shares of Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) fell sharply during Tuesday's session after the company reported second-quarter financial results and cut its FY24 adjusted EPS <a href="https://www.benzinga.com/general/biotech/24/07/40036607/mercks-q2-earnings-revenue-and-eps-beat-helped-by-strong-keytruda-sales-but-acquisition-costs-bit">guidance below estimates</a>.
Merck reported second-quarter sales of $16.1 billion, up 7% year-over-year, beating the consensus estimate of $15.84 billion. Excluding the impact of foreign exchange, sales increased 11%. Merck reported adjusted EPS of $2.28, a shift from an EPS loss of $(2.06), beating the consensus of $2.15, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Merck shares dipped 9.5% to $115.50 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares jumped 147.8% to $2.9250 after the company announced topline results from its Phase 2 OVATION 2 study with IMNN-001. The results showed an 11.1-month improvement in median overall survival compared to standard-of-care alone in the intent-to-treat population.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) surged 97% to $0.1731. AGAPE ATP strengthened wellness division via innovative incubation with emerging local SMEs.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares climbed 53% to $2.60 after the company announced FDA clearance of its IND application for a Phase 2 clinical trial of NGC-Cap in breast cancer.</li>
<li>INVO Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) gained 33% to $1.1513.</li>
<li>Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares gained 29% to $0.3850.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) jumped 28% to $3.4018.</li>
<li>CalciMedica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) jumped 26.3% to $5.24.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) rose 20.6% to $7.16 after the company reported better-than-expected second-quarter financial results.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) rose 19.1% to $2.3050.</li>
<li>Commvault Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) gained 19.1% to $146.77 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates. Also, the company raised its FY25 revenue guidance.</li>
<li>Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) climbed 18.8% to $13.96 after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates.</li>
<li>Meta Data Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIU#NYSE">AIU</a>) gained 18.8% to $5.42.</li>
<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) rose 18.3% to $0.59 after jumping around 6% on Monday.</li>
<li>Inspirato Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) gained 18.3% to $6.20 after jumping over 50% on Monday.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) shares gained 15.9% to $98.13 after the company reported better-than-expected second-quarter financial results and issued its third-quarter earnings guidance above estimates.</li>
<li>NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) gained 16.1% to $17.00 following upbeat earnings.</li>
<li>Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) rose 16.1% to $2.1250 after the company reported better-than-expected quarterly financial results.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) gained 15.5% to $97.79 after the company reported better-than-expected second-quarter financial results. Additionally, the company issued third-quarter earnings guidance above estimates.</li>
<li>Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) climbed 14.1% to $94.56 following better-than-expected second-quarter earnings, issued strong guidance, raised its dividend, increased its buyback authorization and issued strong guidance.</li>
<li>Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) gained 13.4% to $156.48 following -quarter earnings.</li>
<li>Varonis Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) climbed 13.3% to $54.92 as the company reported better-than-expected second-quarter financial results and raised its FY24 guidance on Monday.</li>
<li>Hayward Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) gained 11% to $14.98 after the company reported better-than-expected second-quarter EPS results.</li>
<li>F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) shares rose 10.6% to $196.46 after the company reported better-than-expected third-quarter financial results and raised its FY24 earnings guidance above estimates.</li>
<li>Pharming Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) shares gained 9.8% to $8.28. Pharming Group will report second quarter financial results on Aug. 1.</li>
<li>PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) climbed 8.5% to $63.98 after the company reported better-than-expected second quarter financial results.</li>
<li>Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) rose 8.1% to $104.28 after the company reported better-than-expected second quarter financial results. Additionally, the company revised its FY24 adjusted EPS forecast upward.</li>
<li>Gartner, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) gained 6.4% to $500.83 following better-than-expected quarterly earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares fell 80.8% to $11.44. This sudden decline was triggered by the registration of two private placements with the U.S. Securities and Exchange Commission, which unlocked millions of shares and led to increased selling pressure, Bloomberg reported on Tuesday.</li>
<li>VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) declined 64.8% to $0.1960 after the company was granted protection under Canada&#8217;s CCAA by the Ontario Superior Court. The company received approval for a DIP loan, and Ernst &amp; Young was appointed as the monitor during the restructuring process.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) dipped 40.8% to $0.6158 after the company announced it entered into an exclusive license agreement with Cortice Biosciences.</li>
<li>BIMI Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) tumbled 37% to $0.73.</li>
<li>Bloomz Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) dipped 30.7% to $1.78.</li>
<li>Ekso Bionics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) fell 26.6% to $1.0901 after the company reported worse-than-expected quarterly sales results.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares declined 25.2% to $12.27 after declining 4% on Monday.</li>
<li>VSee Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) fell 23.3% to $2.7999.</li>
<li>SmartRent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) dipped 21.5% to $1.8850 after the company announced a CEO resignation and suspended its 2024 outlook.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) shares fell 21.1% to $28.13 after the company reported worse-than-expected third-quarter earnings results and issued fourth-quarter revenue guidance below estimates.</li>
<li>Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) fell 16.5% to $152.91 after the company reported mixed third-quarter financial results and lowered its FY24 revenue guidance below estimates.</li>
<li>NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) fell 16.2% to $13.82. NIP Group announced the closing of its initial public offering and partial exercise of underwriters' option to purchase additional ADSs.</li>
<li>Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) dipped 16.2% to $43.68 after the company reported worse-than-expected quarterly financial results. Additionally, Raymond James downgraded the stock.</li>
<li>Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) shares fell 14.2% to $32.24 after the company issued roughly in-line guidance.</li>
<li>OneWater Marine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEW#NASDAQ">ONEW</a>) dipped 13.2% to $26.43 after the company reported worse-than-expected third-quarter financial results and issued weak guidance.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) shares fell 11.6% to $37.06 after reporting Phase 2 results for barzolvolimab in chronic inducible urticaria.</li>
<li>Transcat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) declined 11.2% to $120.00 following weak quarterly sales.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) dipped 9.7% to $233.65 following reports indicating Delta Air Lines would seek compensation from the cybersecurity company for last week&#8217;s outage.</li>
<li>Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) shares dipped 9.3% to $50.61 following weak quarterly sales.</li>
<li>Corning Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) fell 8.7% to $38.99 following second-quarter results.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) shares fell 8.3% to $50.40 after the company reported worse-than-expected second-quarter financial results and issued weak third-quarter revenue guidance.</li>
<li>Ecolab Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) declined 6.7% to $231.31 after the company reported worse-than-expected second-quarter sales results.</li>
<li>The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) fell 6.2% to $159.37 following a quarterly revenue miss.</li>
<li>Diageo plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>) fell 5.5% to $124.30 after the company missed annual profit expectations.</li>
<li>Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) shares declined 4.5% to $19.45 following weak quarterly sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40039797/top-3-health-care-stocks-you-may-want-to-dump-this-quarter">Top 3 Health Care Stocks You May Want To Dump This Quarter</a></li>
</ul>

Intraday Update

AMKR

ATPC

BIMI

BLMZ

CALC

CLDX

CNSP

CRWD

EKSO

ENVB

FFIV

HAYW

HLIT

IMNN

INVO

ISPO

JBLU

JTAI

LSCC

MBIN

NIPG

NVAX

ONEW

PCSA

PHAR

PYPL

RMBS

SMRT

TLRY

TRNS

TWOU

VBIV

VRNS

VSEE

Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Tuesday, Repligen Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) reported second-quarter sales of $154.1 million, almost in line with the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus estimate of $154.12 million</a>.
The company reported second-quarter adjusted gross margin of 49.6% <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g40033920/repligen-reports-second-quarter-2024-financial-results" rel="noreferrer noopener">compared to 50.2% a year ago</a>.
The adjusted operating margin fell from 18.5% to 10.1%, and the EBITDA margin was 15.2%, down from 24.2% a year ago.
Tony J. Hunt, CEO of Repligen, said, &#8220;We delivered solid second-quarter revenue of $154 million and first-half revenue of $305 million, achieving our year-to-date sales target. We are very encouraged by orders in the quarter, with continued strength in Pharma demand and a pickup in CDMO activity. New modalities continued to show strong year-over-year momentum in both revenue and orders.&#8221;
The company reported an adjusted EPS of 33 cents, which is in line with the consensus but below $0.53 reported a year ago.
In June, Repligen approved the planned transition of Tony J. Hunt from CEO to Executive Chair, <a href="https://www.benzinga.com/pressreleases/24/06/g39308087/repligen-announces-ceo-transition-plan" target="_blank" rel="noreferrer noopener">effective Sept. 1, 2024</a>.
The company appointed Olivier Loeillot to succeed Hunt as president and CEO.
Repligen &#8220;strengthened&#8221; its Proteins business with new product launches and has a pending acquisition of Tantti Laboratory, Hunt noted. The second half of 2024 will &#8220;outpace the first half on both revenue and orders,&#8221; he added.
Guidance: Repligen expects 2024 revenues of $620 million—$635 million, compared to prior guidance of $620 million—$650 million and the consensus of $636.6 million.
The company reaffirms 2024 adjusted EPS guidance of $1.42-$1.49 versus consensus of $1.45.
William Blair views Repligen&#8217;s guide as among the least safe in the space, given that it was contingent upon ordering improving in the second/third quarter. Therefore, the analyst is not surprised by the guidance cut. The analyst notes that the magnitude of the cut was less than feared.
Despite the guidance cut, management noted an improved book-to-bill of 1.02x (a step up from the first-quarter book-to-bill of 0.99x). Further, management reiterated that it expects double-digit non-COVID revenue growth in the year&#8217;s second half.
The analyst keeps <a target="_blank" href="https://www.benzinga.com/quote/RGEN/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
Price Action: RGEN stock is up 11.3% at $153.61 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/40037079/pfizer-marks-first-revenue-growth-since-covid-revenue-peak-in-2022-lifts-annual-guidance" target="_blank" rel="noreferrer noopener">Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance</a>.</li>
</ul>
Image:

Analyst Color

Guidance

Health Care

Repligen Lowers Guidance On China Weakness, Analyst Expects

Stephens &amp; Co. analyst Jacob Johnson reiterates Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Overweight and maintains $170 price target.

Stephens & Co. Reiterates Overweight on Repligen, Maintains $170 Price Target

U.S. stocks were mixed, with the Dow Jones index gaining more than 100 points on Tuesday.
Shares of PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) rose sharply during Tuesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/40034498/fintech-giant-paypals-q2-earnings-revenue-and-eps-beat-payment-volumes-and-transactions-surge-guida">second quarter financial results</a>.
PayPal reported fiscal second-quarter revenue growth of 8% year over year to $7.89 billion, beating the analyst consensus estimate of $7.81 billion. The company reported a quarterly adjusted EPS of $1.19, beating analyst consensus estimates of 98 cents, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
PayPal shares surged 8.5% to $63.98 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) jumped 20.6% to $7.16 after the company reported better-than-expected second-quarter financial results.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) jumped 19.1% to $2.3050.</li>
<li>Commvault Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) jumped 19.1% to $146.77 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates. Also, the company raised its FY25 revenue guidance.</li>
<li>Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) jumped 18.8% to $13.96 after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) shares rose 15.9% to $98.13 after the company reported better-than-expected second-quarter financial results and issued its third-quarter earnings guidance above estimates.</li>
<li>NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) rose 16.1% to $17.00 following upbeat earnings.</li>
<li>Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) rose 16.1% to $2.1250 after the company reported better-than-expected quarterly financial results.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) climbed 15.5% to $97.79 after the company reported better-than-expected second-quarter financial results. Additionally, the company issued third-quarter earnings guidance above estimates.</li>
<li>Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) gained 14.1% to $94.56 following better-than-expected second-quarter earnings, issued strong guidance, raised its dividend, increased its buyback authorization and issued strong guidance.</li>
<li>Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) rose 13.4% to $156.48 following -quarter earnings.</li>
<li>Varonis Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) jumped 13.3% to $54.92 as the company reported better-than-expected second-quarter financial results and raised its FY24 guidance on Monday.</li>
<li>Hayward Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) rose 11% to $14.98 after the company reported better-than-expected second-quarter EPS results.</li>
<li>F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) shares climbed 10.6% to $196.46 after the company reported better-than-expected third-quarter financial results and raised its FY24 earnings guidance above estimates.</li>
<li>Heidrick &amp; Struggles International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSII#NASDAQ">HSII</a>) gained 10.2% to $39.41 following upbeat quarterly results.</li>
<li>Pharming Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) shares rose 9.8% to $8.28. Pharming Group will report second quarter financial results on Aug. 1.</li>
<li>CNO Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNO#NYSE">CNO</a>) jumped 9% to $33.78 following upbeat quarterly results.</li>
<li>Latham Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) surged 8.6% to $3.78.</li>
<li>Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) gained 8.1% to $104.28 after the company reported better-than-expected second quarter financial results. Additionally, the company revised its FY24 adjusted EPS forecast upward.</li>
<li>Eagle Materials Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) jumped 8.1% to $268.95 after the company reported better-than-expected first-quarter EPS results.</li>
<li>NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) rose 8% to $22.47.</li>
<li>Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) gained 7.3% to $3.0802. Spirit Airlines announced low-fare travel with new premium offerings starting Aug. 2024.</li>
<li>Zebra Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) jumped 6.4% to $356.62 after the company reported better-than-expected quarterly financial results. Additionally, the company raised its FY24 guidance.</li>
<li>Gartner, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) rose 6.4% to $500.83 following better-than-expected quarterly earnings.</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) climbed 4.9% to $147.31 after the company reported better-than-expected quarterly financial results.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) gained 4.8% to $69.13.</li>
<li>American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) gained 4.3% to $10.88.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/40038432/mcdonalds-analysts-cut-their-forecasts-after-downbeat-earnings">McDonald&#8217;s Analysts Cut Their Forecasts After Downbeat Earnings</a></li>
</ul>

HSII

NVCR

PEGA

SAVE

SWIM

ZBRA

PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday

WIIM

Repligen shares are trading higher. The company reported Q2 financial results.

FINANCIAL GUIDANCE FOR FULL YEAR 2024
All Adjusted figures are non-GAAP
Our financial guidance for the full year 2024 is based on expectations for our existing business.&nbsp;Our GAAP and Adjusted guidance include the expected impact of businesses acquired in 2023 (FlexBiosys and Metenova) and excludes the impact of any potential or pending business acquisitions in 2024, and future fluctuations in foreign currency exchange rates.&nbsp;
<table>
<tbody>
<tr>
<td colspan="2">CURRENT GUIDANCE
			(at July 30, 2024)</td>
</tr>
<tr>
<td>FY 2024</td>
<td colspan="1">GAAP</td>
<td colspan="1">Adjusted (non-GAAP)</td>
</tr>
<tr>
<td>Total Reported Revenue</td>
<td colspan="1">$620M - $635M</td>
<td colspan="1">$620M - $635M</td>
</tr>
<tr>
<td>Year-over-Year Change</td>
<td colspan="1">(3%) - (1%)</td>
<td colspan="1">(3%) - (1%)</td>
</tr>
<tr>
<td>Base Revenue Growth</td>
<td>-</td>
<td colspan="1">(1%) - 1%</td>
</tr>
<tr>
<td>Gross Margin</td>
<td colspan="1">49% - 50%</td>
<td colspan="1">49% - 50%</td>
</tr>
<tr>
<td>Income from Operations</td>
<td colspan="1">$12M - $17M</td>
<td colspan="1">$76M - $81M</td>
</tr>
<tr>
<td>Operating Margin</td>
<td colspan="1">2% - 3%</td>
<td colspan="1">12% - 13%</td>
</tr>
<tr>
<td>Other Income (Expense)</td>
<td colspan="1">$5M</td>
<td colspan="1">$24M</td>
</tr>
<tr>
<td>Adjusted EBITDA Margin</td>
<td>-</td>
<td colspan="1">17% - 18%</td>
</tr>
<tr>
<td>Tax Rate on Pre-Tax Income</td>
<td>35%</td>
<td>20%</td>
</tr>
<tr>
<td>Net Income</td>
<td colspan="1">$9.5M - $13.5M</td>
<td colspan="1">$80M - $84M</td>
</tr>
<tr>
<td>Earnings Per Share - Diluted</td>
<td colspan="1">$0.17 - $0.24</td>
<td colspan="1">$1.42 - $1.49</td>
</tr>
</tbody>
</table>

Repligen Expects 2024 Revenues Of $620M-$635M Versus Prior Guidance Of $620M-$650M And Consensus Of $636.562M, Reaffirms 2024 Adjusted EPS Guidance Of $1.42-$1.49 Versus Consensus Of $1.45

Repligen Q2 2024 Adj. EPS $0.33, Inline, Sales $154.073M Miss $154.121M Estimate

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Repligen (RGEN – Research Report), with a price target o...

RBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)

Voya Large Cap Growth Strategy Q2 2024 Commentary

Voya SmallCap Opportunities Portfolio Q2 2024 Commentary

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biomea Fusion (BMEA – Research Report) and Repligen (RGEN – Resea...

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Repligen (RGEN)

Voya Small Cap Growth Fund Quarterly Q2 2024 Commentary

Morgan Stanley identifies 39 stocks likely to face tax loss selling pressure

Morgan Stanley's list of tax loss selling stocks

TimesSquare U.S. Mid Cap Growth Strategy Q3 2024 Commentary

Wolfe's tax loss selling stocks within communications, discretionary, staples, energy, financials, health care

In a report released yesterday, Rachel Vatnsdal from J.P. Morgan maintained a Buy rating on Repligen (RGEN – Research Report), with a price target ...

Comments

Repligen

Notizie

Ultime notizie per Repligen (NASDAQ:RGEN) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO